229 related articles for article (PubMed ID: 24589526)
1. Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis.
Capo A; Di Nicola M; Auriemma M; Piaserico S; Cuccurullo C; Santilli F; Davi G; Amerio P
Eur J Dermatol; 2014; 24(1):133-5. PubMed ID: 24589526
[No Abstract] [Full Text] [Related]
2. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
Girolomoni G; Abeni D
Arch Dermatol; 2001 Jun; 137(6):784-5. PubMed ID: 11405771
[No Abstract] [Full Text] [Related]
3. TNFalpha therapy in psoriatic arthritis and psoriasis.
Mease P
Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
[No Abstract] [Full Text] [Related]
4. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach.
Gordon KB; Ruderman EM
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S85-91. PubMed ID: 16488334
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
6. Malignancies developing in obese patients with psoriasis while on antitumour necrosis factor-α therapies: a case series.
Sadlier M; Lally A; Kirby B
Br J Dermatol; 2012 Oct; 167(4):937-8. PubMed ID: 22428935
[No Abstract] [Full Text] [Related]
7. TNF-alpha inhibitors in dermatology.
Cordoro KM; Feldman SR
Skin Therapy Lett; 2007 Sep; 12(7):4-6. PubMed ID: 17940711
[TBL] [Abstract][Full Text] [Related]
8. Combination biologic treatment of refractory psoriasis and psoriatic arthritis.
Cuchacovich R; Garcia-Valladares I; Espinoza LR
J Rheumatol; 2012 Jan; 39(1):187-93. PubMed ID: 22210681
[No Abstract] [Full Text] [Related]
9. Treatment of nail psoriasis with tumor necrosis factor-alpha blocker agents: an open-label, unblinded, comparative study.
Ozmen I; Erbil AH; Koc E; Tunca M
J Dermatol; 2013 Sep; 40(9):755-6. PubMed ID: 23834032
[No Abstract] [Full Text] [Related]
10. Treatment of spondyloarthritides with anti-TNFalpha biologic agents.
Braun J
Reumatismo; 2006; 58 Spec No.1():71-2. PubMed ID: 23631067
[No Abstract] [Full Text] [Related]
11. [Psoriasis updates].
Boulinguez S
Ann Dermatol Venereol; 2010 May; 137(5 Suppl 1):1-4. PubMed ID: 20510173
[No Abstract] [Full Text] [Related]
12. Autoantibodies in psoriatic patients treated with anti-TNF-α therapy.
Bardazzi F; Odorici G; Virdi A; Antonucci VA; Tengattini V; Patrizi A; Balestri R
J Dtsch Dermatol Ges; 2014 May; 12(5):401-6. PubMed ID: 24797746
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
[No Abstract] [Full Text] [Related]
14. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
Gottlieb A; Korman NJ; Gordon KB; Feldman SR; Lebwohl M; Koo JY; Van Voorhees AS; Elmets CA; Leonardi CL; Beutner KR; Bhushan R; Menter A
J Am Acad Dermatol; 2008 May; 58(5):851-64. PubMed ID: 18423261
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing seasonal patterns of relapse in anti-TNF psoriatic responders after temporary drug discontinuation.
Ruano J; Velez A; Casas E; Rodriguez-Martin A; Salido R; Isla-Tejera B; Espejo-Alvarez J; Gómez F; Jiménez-Puya R; Moreno-Giménez JC
J Eur Acad Dermatol Venereol; 2014 Apr; 28(4):516-8. PubMed ID: 23841941
[No Abstract] [Full Text] [Related]
16. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors.
Meyer MW; Zachariae C; Bendtzen K; Skov L
Acta Derm Venereol; 2012 Jul; 92(4):362-4. PubMed ID: 22864558
[No Abstract] [Full Text] [Related]
17. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?
De Simone C; Amerio P; Amoruso G; Bardazzi F; Campanati A; Conti A; Gisondi P; Gualdi G; Guarneri C; Leoni L; Loconsole F; Mazzotta A; Musumeci ML; Piaserico S; Potenza C; Prestinari F
Expert Opin Biol Ther; 2013 Dec; 13(12):1673-82. PubMed ID: 24107126
[TBL] [Abstract][Full Text] [Related]
18. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
[TBL] [Abstract][Full Text] [Related]
19. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
Lehnen M; Goos M; Dissemond J
Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
[No Abstract] [Full Text] [Related]
20. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
Cho YT; Chen CH; Chiu HY; Tsai TF
J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
